Cover Image
市場調查報告書

生物相似藥市場分析:產品,應用領域,地區別預測

Biosimilars Market Analysis By Product (Recombinant Non-Glycosylated Proteins - Insulin, G-CSF, Interferons, HGH, Recombinant Glycosylated Proteins - Erythropoietin, Monoclonal Antibodies, Follitropin) & By Application Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 544803
出版日期 內容資訊 英文 92 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物相似藥市場分析:產品,應用領域,地區別預測 Biosimilars Market Analysis By Product (Recombinant Non-Glycosylated Proteins - Insulin, G-CSF, Interferons, HGH, Recombinant Glycosylated Proteins - Erythropoietin, Monoclonal Antibodies, Follitropin) & By Application Segment Forecasts To 2024
出版日期: 2016年06月10日 內容資訊: 英文 92 Pages
簡介

本報告提供生物相似藥的全球市場調查,提供整體市場趨勢,各產品·應用領域·地區別詳細趨勢,收益額的變化與預測,推動市場要素及阻礙因素分析,競爭情形,主要企業簡介等系統性資訊。

第1章 調查手法·調查範圍

第2章 摘要整理

第3章 市場概要

第4章 生物相似藥市場趨勢

  • 市場區隔·範圍
  • 市場動態
    • 推動因素
    • 阻礙因素
  • 市場滲透率·成長率預測
  • SWOT分析
  • 波特的五力分析

第5章 生物相似藥市場:各產品

  • 市場趨勢分析:各產品
  • 重組的非糖基化蛋白質
    • 胰島素
    • 生長激素
    • 顆粒細胞增生因子(G-CSF)
    • 干擾素
  • 重組的糖基化蛋白質
    • 促血紅細胞生長素(EPO)
    • 單株抗體
    • 促濾泡素

第6章 生物相似藥市場:應用各領域

  • 市場趨勢分析:應用各領域
  • 癌症
  • 血液疾病
  • 下垂體性矮小症
  • 慢性疾病·自體免疫疾病
  • 其他

第7章 生物相似藥市場:各地區

  • 各地區的市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第8章 競爭情形

  • 策略的組成架構
  • 參與企業的區分
  • 企業簡介
    • Amgen, Inc.
    • Biocon Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co.
    • Hospira, Inc.
    • Mylan Pharmaceuticals, Inc.
    • Dr. Reddy's Laboratories, Inc.
    • Sandoz, Inc.
    • Celltrion Healthcare Co. Ltd.
    • AbbVie, Inc.
目錄
Product Code: 978-1-68038-916-6

The biosimilars market is expected to reach USD 41.7 billion by 2024, according to a new report by Grand View Research, Inc. The global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024. The most significant factor leading to the growth of this industry is the fact that major biological drugs are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to cut down healthcare costs across the medical systems in the world, and the favorable clinical outcomes demonstrated through clinical trials for the biosimilar drugs is expected to boost the industry.

For the purpose of this study, the major countries considered are the U.S., Canada, the UK, Germany, India, China, Brazil, and Russia. It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.

The industry is segmented on the basis of type of products and applications. With regard to the product type, the recombinant non-glycosylated segment is projected to flourish rapidly during the study period. On the other hand, the recombinant glycosylated proteins segment is estimated to grow at a significant CAGR during the period 2015 to 2024 due to the increasing, wide spread incidence of cancer cases (24 million by 2035), which is identified as the crucial factor driving the growth of this sector.

Further key findings from the study suggest:

North America is anticipated to be the fastest growing market during the forecast period. The biosimilars market has gained significant momentum in the U.S., presenting new opportunities for R&D and the manufacturing sector of biosimilars.

The European market is the most advanced one as it has been the first to formulate a regulatory pathway and adopt the use of biosimilars for more than 8 years now. Germany accounts for the maximum share in the biosimilars industry, followed by the rest of the European countries (UK, France, Spain, and Italy).

The Asia Pacific market is expected to witness a lucrative growth during the period 2015 to 2024. India and China are the key countries identified that are expected to lead the industry growth in the study period.

The market for oncology is estimated to soar at a rapid pace in accordance with the increasing incidence of cancer cases in the world. Additionally, the demand for cost-effective cancer treatments is expected to further fuel the industry growth.

The biosimilars market comprises several local as well as global players. Some major players of this market include Amgen, Inc., Beacon Ltd., Tea Pharmaceutical Industries Ltd., Merck & Co., Milan, Inc., Dr. Reddy's Laboratories, Inc., Sandoz, Inc., and Celltrion Healthcare Co., Ltd.

Grand View Research has segmented the global biosimilars market on the basis of end-user, application, and region:

Biosimilars Market, by Product (Revenue, USD Million, 2013 - 2024)

Recombinant Non-Glycosylated Proteins

Insulin

Human Growth Hormones

Granulocyte Colony-stimulating Factor (G-CSF)

Interferons

Recombinant Glycosylated Proteins

Erythropoietin

Monoclonal Antibodies

Follitropin

Biosimilars Market, by Application (Revenue, USD Million, 2013 - 2024)

Oncology

Blood Disorders

Growth Hormone Deficiency

Chronic and Autoimmune Disorders

Others

Biosimilars Market, by Region (Revenue, USD Million, 2013 - 2024)

North America

U.S.

Canada

Europe

UK

Germany

Asia Pacific

China

India

Rest of the World

Brazil

Russia

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research scope & assumption
  • 1.3. List of data sources

Chapter 2. Executive Summary

  • 2.1. Biosimilars Market - Industry Summary and Key Buying Criteria, 2013 - 2024

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market segmentation& scopes
  • 4.2. Biosimilars: Market dynamics
    • 4.2.1. Market driver analysis
      • 4.2.1.1. Increasing emphasis on cutting down healthcare expenditures
      • 4.2.1.2. Cost effectiveness of biosimilar drugs
      • 4.2.1.3. Positive outcome in the ongoing clinical trials
      • 4.2.1.4. Increasing R&D investments
      • 4.2.1.5. Patent expiration of biologics to boost the biosimilars market
    • 4.2.2. Market restraint analysis
      • 4.2.2.1. High manufacturing complexities and costs
      • 4.2.2.2. Presence of non-original biologics and biobetters
  • 4.3. Penetration & growth prospect mapping
  • 4.4. Biosimilars - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 4.5. Industry Analysis - Porter's

Chapter 5. Biosimilars Market: Product Estimates & Trend Analysis

  • 5.1. Biosimilars market: Product movement analysis
  • 5.2. Recombinant Non-Glycosylated Proteins
    • 5.2.1. Recombinant Non-Glycosylated Proteins Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.2.1.1. Insulin
      • 5.2.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.2.1.2. Human Growth Hormones
      • 5.2.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.2.1.3. Granulocyte Colony-stimulating Factor (G-CSF)
      • 5.2.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.2.1.4. Interferons
      • 5.2.1.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
  • 5.3. Recombinant Glycosylated Proteins
    • 5.3.1. Recombinant Glycosylated Proteins, Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.3.1.1. Erythropoietin
      • 5.3.1.1.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.3.1.2. Monoclonal Antibodies
      • 5.3.1.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
      • 5.3.1.3. Follitropin
      • 5.3.1.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)

Chapter 6. Biosimilars Market: Application Estimates & Trend Analysis

  • 6.1. Biosimilars market: Application movement analysis
  • 6.2. Oncology
    • 6.2.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
  • 6.3. Blood Disorders
    • 6.3.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
  • 6.4. Growth Hormone Deficiency
    • 6.4.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
  • 6.5. Chronic And Autoimmune Disorders
    • 6.5.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Estimates and Forecast, 2013 to 2024 (USD Million)

Chapter 7. Biosimilars: Regional Estimates & Trend Analysis, by Product & Application

  • 7.1. Biosimilars Market Share (%) Analysis, by Region, 2016&2024
  • 7.2. North America
    • 7.2.1. U.S.
      • 7.2.1.1. U.S. biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.2.1.2. U.S. biosimilars market, by application, 2013 - 2024 (USD Million)
    • 7.2.2. Canada
      • 7.2.2.1. Canada biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.2.2.2. Canada biosimilars market, by application, 2013 - 2024 (USD Million)
  • 7.3. Europe
    • 7.3.1. Germany
      • 7.3.1.1. Germany biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.3.1.2. Germany biosimilars market, by application, 2013 - 2024 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.3.2.2. UK biosimilars market, by application, 2013 - 2024 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. China
      • 7.4.1.1. China biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.4.1.2. China biosimilars market, by application, 2013 - 2024 (USD Million)
    • 7.4.2. India
      • 7.4.2.1. India biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.4.2.2. India biosimilars market, by application, 2013 - 2024 (USD Million)
  • 7.5. Rest of the World
    • 7.5.1. Brazil
      • 7.5.1.1. Brazil biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.5.1.2. Brazil biosimilars market, by application, 2013 - 2024 (USD Million)
    • 7.5.2. Russia
      • 7.5.2.1. Russia biosimilars market, by product, 2013 - 2024 (USD Million)
      • 7.5.2.2. Russia biosimilars market, by application, 2013 - 2024 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Strategy framework
  • 8.2. Market participation categorization
  • 8.3. Company Profiles
    • 8.3.1. Amgen, Inc.
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Biocon Ltd.
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Teva Pharmaceutical Industries Ltd.
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Merck & Co.
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Hospira, Inc.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Mylan Pharmaceuticals, Inc.
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Dr. Reddy's Laboratories, Inc.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Sandoz, Inc.
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Celltrion Healthcare Co. Ltd.
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. AbbVie, Inc.
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • 1. Biosimilars - industry snapshot & key buying criteria, 2013 - 2024
  • 2. Biosimilars market revenue, by product, 2013 - 2024 (USD Million)
  • 3. Biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 4. Biosimilars market, by region, 2013 - 2024 (USD Million)
  • 5. Biosimilars - key market driver analysis
  • 6. Biosimilars - key market restraint analysis
  • 7. North America biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 8. North America biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 9. U.S. biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 10. U.S. biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 11. Canada biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 12. Canada biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 13. Europe biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 14. Europe biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 15. Germany biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 16. Germany biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 17. UK biosimilars market revenue, by product, 2013 - 2024 (USD Million)
  • 18. UK biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 19. AsiaPacific biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 20. Asia Pacific biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 21. China biosimilars market revenue, by product, 2013 - 2024 (USD Million)
  • 22. China biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 23. India biosimilars market revenue, by product, 2013 - 2024 (USD Million)
  • 24. India biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 25. Rest of the world biosimilars market revenue, by product, 2013 - 2024 (USD Million)
  • 26. Rest of the world biosimilars market revenue, by application, 2013 - 2024 (USD Million)
  • 27. Brazil biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 28. Brazil biosimilars market revenue, by application,2013 - 2024 (USD Million)
  • 29. Russia biosimilars market revenue, by product,2013 - 2024 (USD Million)
  • 30. Russia biosimilars market revenue, by application , 2013 - 2024 (USD Million)

List of Figures

  • 1. Biosimilars: Market segmentation
  • 2. Biosimilars, 2013 - 2024 (USD Million)
  • 3. Biosimilars market: Industry trend analysis
  • 4. Biosimilars market: PESTEL analysis
  • 5. Global Biosimilars market: Porter's analysis
  • 6. Biosimilars company market share, 2015
  • 7. Key Opportunities Prioritized
  • 8. Biosimilars market revenue share by product, 2016 & 2024
  • 9. Biosimilars market by product market revenue, 2013 to 2024 (USD Million)
  • 10. Biosimilars market by application market revenue, 2013 to 2024 (USD Million)
  • 11. Biosimilars market share, by region, 2016 & 2024
Back to Top